Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults (REPRIEVE)

What is the purpose of this trial?

The study is funded by the National Heart, Lung, and Blood Institute, with additional infrastructure support provided by the National Institute of Allergy and Infectious Diseases.

People infected with HIV are at risk for cardiovascular disease (CVD). This study will evaluate the use of pitavastatin to reduce the risk of CVD in adults infected with HIV who are on antiretroviral therapy (ART).

Participation Guidelines

Ages: 40 - 75 years

Gender: Both

Massachusetts General Hospital

Start Date: 02/19/2015

End Date: 04/01/2020

Last Updated: 05/13/2018

Study HIC#: 1501015241

Get Involved

For more information about this study, contact:
Laurie Andrews
+1 203-785-3557

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image


Michael Kozal

Principal Investigator